Antimalarial agent 25, a derivative of 1,4-naphthoquinones, demonstrates oral activity and is effective against malaria. It exhibits cytotoxic properties specifically targeting P. falciparum and effectively inhibits parasitemia induced by P. burghei in vivo [1].

Antimalarial agent 25 (compound 8) exhibits an IC₅₀ of 4.2 μM against P. falciparum, while demonstrating CC₅₀ values of 289.2 μM for HepG2 cells and 400.6 μM for Vero cells [1]. In uninfected human red blood cells, concentrations ranging from 15.62 to 250 μM show hemolytic activity below 40% when treated for 2 hours [1]. At concentrations of 30 to 0.411 μg/mL over 48 hours, this agent causes substantial cytoplasmic degradation and loss of membrane integrity in the W2 strain of P. falciparum [1]. Cell viability assays indicate that the W2 strain (chloroquine-resistant) displays significant morphological changes, including dense cytoplasm with possible undefined organelles in a degenerating stage and potentially deteriorated food vacuoles [1].

Antimalarial agent 25, administered orally at a dose of 30 mg/kg four times daily, enhances antimalarial activity against Plasmodium berghei in mice. In a single 300 mg/kg oral dose, this agent does not cause notable pathological changes or histopathological damage in female mice. In a model using mice infected with Plasmodium berghei ANKA, the treatment reduced parasitemia by 33% on the seventh day post-treatment.